Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. The NDA-filing process is ongoing and expected to be completed by the end of February 2008.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal th
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... 30, 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have ... June 30, , Six-months ended June 30, ( ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 ...
(Date:8/22/2014)... University of Surrey have discovered how the receptors responsible ... genes. , The new study, published today in ... activity in turn regulates the cycle of all cells ... that the local biological clock and its control are ... clock in bladder physiology and ageing. , ...
(Date:8/22/2014)... a study published today (August 22nd), in the ... the Champalimaud Neuroscience Programme establish the effect of ... of advanced genetic and optical techniques., "Serotonin is ... a wide range of brain functions, from the ... of complex emotional behaviours, This neurotransmitter is also ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2From happiness to pain: Understanding serotonin's function 2
... Wis. -- Gov. Jim Doyle says taxpayers will ... total of nearly $80 million over the lifetime of ... and services, including a number of technology areas. , ... Accountability, Consolidation, and Efficiency (ACE) Initiative to ensure ...
... of Milwaukee is one of six first-year college students from ... Online's "Project Freshman," a new documentary series that will be ... Friday, Sept. 23. New episodes will air every Thursday. The ... were given digital video cameras and were trained in their ...
... -- The Wisconsin Technology Council has teamed with PropertyDrive, ... database of commercial real estate on the Tech Council ... on the site's Resource Center, Commercial Property Search. , ... locate or expand in Wisconsin the ability to search ...
Cached Biology Technology:
(Date:8/22/2014)... 22, 2014 ... announced the addition of the  "Biometrics ... to their offering.       ... a technology that helps in the ... physical or behavioral features. It involves ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information for ... University of California, Riverside in its 2014 list of ... times." , To generate the list, the company analyzed ... whose published work has had enormous impact. , The ... individuals who published the greatest number of highly cited ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... is available in Polish . A ... mouse embryos can repair damaged brain circuitry and partially normalize ... obese due to a genetic deficiency. This proof-of-principle discovery represents ... which researchers hope might one day be used to repair ...
... National Taiwan University researchers have successfully manipulated the life span ... remove and restore protein functions related to yeast aging. ... in yeast acts like a life span clock: It is ... age. In a report in the September 16 edition ...
... and the University of Geneva have discovered a genetic mechanism ... genes play only a secondary role. The research published in ... mechanism is found in a DNA sequence that was thought, ... enhancers which, when combined with one another, modulate the activity ...
Cached Biology News:Metabolic defects in mice corrected with transplanted embryonic neurons 2Hopkins scientists turn on fountain of youth in yeast 2Finger (mal)formation reveals surprise function of desert DNA 2
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: